DUBLIN, Nov. 8, 2018 /PRNewswire/ —
The “The Global Ophthalmic Drugs Market” report has been added to ResearchAndMarkets.com's offering.
The global ophthalmic drugs market is expected to witness a CAGR of 6.3% during the forecast period to reach revenue of $30,134.5 million by 2024.
Development of innovative ophthalmic drug delivery methods has aided the drug manufacturers in developing effective and advanced therapeutic tactics. American Academy of Ophthalmology has stated that, nearly 11 million individuals in the US are correctly suffering with age-related macular degeneration (AMD), while almost 10% of that population have wet AMD. Such inclinations eye ailments worldwide contribute to the development of the ophthalmic drugs market.
The other significant aspects that help in the improvement the market are high pervasiveness of glaucoma globally and intensification in evolution in the development of combination drugs for the glaucoma.
Additionally, the changing aspects in the demography worldwide are driving the growth of the market. Nevertheless, hazard of side effects related to ophthalmic drugs and loss of patent for blockbuster drugs are hampering the market growth.
The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the ophthalmic drugs market, followed by Europe, Asia Pacific, and Rest of the World. North America alone occupies more than 35% of the market, with a significant contribution from the US to the market growth.
Indication Type Analysis
Based on the Indication type, the market is segmented into dry eyes, glaucoma, eye infection/inflammation, retinal disorders, and others. The market is dominated by retinal disorders and is also expected to be the fastest growing segment. However, glaucoma is the second largest segment, owing to the high prevalence of diseases and lack of awareness among the people.
Novartis AG, Pfizer, Allergan Inc., Valeant Pharmaceutical International, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceutical, Akron Inc. and Johnson & Johnson are the key players in the market.
Shire PLC, Daiichi Sankyo, Inc., Bayer AG, F.Hoffmann-La Roche, and Sun Pharmaceuticals are the companies to watch for.
In future, several blockbuster drugs that have dominated the market, are expected to lose their patents. The patents of successful products accounted for over $6 billion.
The loss of patent is the most important aspect imposing major threat to the leaders in the ophthalmic drugs market. Lupin Pharmaceuticals received US FDA approval on February 2015, for its bimatoprost ophthalmic solution 0.03%, the generic version of Lumigan. This affected the Allergan's market.
Formycon AG, a German biosimilars developing company is currently developing biosimilar for Eylea by Regeneron Pharmaceuticals. Allergan, meanwhile, is under the threat from Akron, which is developing a generic version of Restasis. The release of such product is likely to generate an strong burden on the market players.
Key Topics Covered
1 Industry Outlook
1.1 Industry Overview
1.1.1 Global Driver For Pharmaceutical Demand:
1.1.2 Pharmaceutical Spending Region Wise
1.1.3 R&D Pipeline In Pharmaceutical Industry
1.1.4 Top Pharma Drugs By Sales In 2017 ($Million)
1.2 Industry Trends
1.3 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Research
3.2 Segmented Addressable Market
3.2.1 Trends In The Ophthalmic Drugs Market
3.3 Related Markets
3.3.1 Bacterial Conjunctivitis Drugs
18.104.22.168 Trends Of Bacterial Conjunctivitis Drugs Market
3.3.2 Contact Lenses
22.214.171.124 Trends Of Contact Lens Market
4 Market Outline
4.1 Ophthalmic Drugs Approved By FDA
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 Pest Analysis
5 Market Characteristics
5.1 Market Dynamics
126.96.36.199 Increasing Prevalence Of Eye Diseases
188.8.131.52 Increasing Prevalence Of Cataract
184.108.40.206 Increasing Aging Population
220.127.116.11 Increasing Mergers & Acquisitions
18.104.22.168 Complex Drug Development Process
22.214.171.124 Loss Of Patent For Blockbuster Drugs
5.2 Dro – Impact Analysis
5.3 Key Stakeholders
6 Indication: Market Size And Analysis
6.2 Dry Eyes
6.4 Eye Infection/ Inflammation
6.5 Retinal Disorder
7 Regions: Market Size And Analysis
7.2 North America
7.4 Asia Pacific
7.5 Rest Of The World
8 Competitive Landscape
9 Vendor Profiles
9.1 Allergan PLC
9.1.2 Business Units
9.1.3 Geographic Revenue
9.1.4 Business Focus
9.1.5 Swot Analysis
9.1.6 Business Strategies
9.2 Novartis AG
9.2.2 Business Units
9.2.3 Geographic Presence
9.2.4 Business Focus
9.2.5 Swot Analysis
9.2.6 Business Strategy
9.3 Pfizer Inc.
9.3.2 Business Units
9.3.3 Geographic Presence
9.3.4 Business Focus
9.3.5 Swot Analysis
9.3.6 Business Strategies
9.4 Valeant Pharmaceuticals International Inc. (Bausch Health)
9.4.2 Business Units
9.4.3 Geographic Presence
9.4.4 Business Focus
9.4.5 Swot Analysis
9.4.6 Business Strategy
9.5 Santen Pharmaceutical Co. Ltd.
9.5.2 Business Units
9.5.3 Geographic Presence
9.5.4 Business Focus
9.5.5 Swot Analysis
9.5.6 Business Strategies
9.6 Akorn Inc.
9.6.2 Business Focus
9.6.3 Swot Analysis
9.6.4 Business Strategy
9.7 Johnson & Johnson
9.7.2 Business Units
9.7.3 Geographic Revenue
9.7.4 Business Focus
9.7.5 Swot Analysis
9.7.6 Business Strategies
10 Companies To Watch For
10.1 Shire PLC
10.2 Daiichi Sankyo, Inc.
10.3 Bayer AG
10.4 F. Hoffmann-La Roche (Genentech)
10.5 Sun Pharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/research/f497nm/ophthalmic_drugs?w=5
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets